METHODS:
Analysis based on publicly available annexes of the Positive Drug List and published Protocols of the pricing and reimbursement competent authority (NCPR) was done in order to extract the new INN for 2015. Systematic review analysis using official websites for the HTA and Pharmacoeconomic approach in 10 EU Member States in Central and Eastern Europe (Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Lithuania, Latvia, Poland, Slovakia, Slovenia) has been performed by different competent authorities (CAs). Analysis based on publicly available pharmacoeconomic guidelines in Bulgaria and in other CEEC was performed . Out of all MPs (n=44) included in the PDL for the period 2013 till October 2015, 84.% (n=37) were approved for 100%, 6.8.% (n=3) for 75%; 6.8% (n=3) for 50%; 2.2% (n=1) for 25% reimbursement level. On average the new INN, included in the PDL in 2015, are applied within 2 to 3 years after the EU approval, with exception of Posaconazole. (Table 1) At the moment the reimbursement process is under serious revision and new HTA competent authority is expecting to be set up soon.
RESULTS.
Patient access to the new INN, included in the PDL has been extented to the beginning of the next consecutive year. According to the template of the expert report on the website of the Bulgarian competent authority (NCPR) Pharmacoeconomic assessment is a part of the reimbursement process and is within the jurisdiction of different CEE institutions. The HTA bodies in CEEC and their pharmacoeconomic guidelines in all of the surveyed countries have been compared. (Table 2) The Pharmacoeconomic assessment (PE) is also part of the reimbursement process and is closely or directly linked to reimbursement decision which, in turn, has a direct impact to marker access. (3) The diversity of different reimbursement institutions in surveyed CEEC is additionally complicated by the fact that the HTA PE-guidelines or recommendations are published in local language only (Bulgaria-2015 , Hungary-2013 , Slovakia-2010 , Slovenia-2011 and they are vary from country to country. In the Baltic countries, Estonia, Latvia and Lithuania, a single English pharmacoeconomic guideline for all these countries has been published in 2002, which makes the process more harmonised for the Baltic countries. (Table 2 
